Significantly, pharmacologic targeting of Aurora-A kinase activity with alisertib restored chemosensitivity, demonstrating that Aurora-A activity is required to promote Raf/MAPK-induced chemoresistance in ER+ breast cancer cells. The gene discussed is RAF1; the disease is breast carcinoma.